Antiprothrombin antibody testing: detection and clinical utility

Area of Science:

• Immunology
• Clinical Chemistry
• Rheumatology

Background:

• Antiphospholipid syndrome (APS) diagnosis relies on specific laboratory tests like anticardiolipin antibodies (aCL), anti-beta2 glycoprotein I antibodies, and lupus anticoagulant (LA).
• Recent research identified antibodies against phosphatidylserine-prothrombin complex (aPS/PT) as potentially significant markers for APS.
• These aPS/PT antibodies, distinct from anti-prothrombin antibodies, show a strong association with APS and LA.

Purpose of the Study:

• To evaluate the diagnostic performance of aPS/PT antibodies in patients with various autoimmune disorders.
• To compare the diagnostic utility of aPS/PT with established APS laboratory criteria.
• To explore the potential of aPS/PT as a future criterion for APS classification.

Main Methods:

• Assessment of sensitivity and specificity of aPS/PT for APS diagnosis.
• Analysis conducted on a cohort of patients diagnosed with diverse autoimmune conditions.
• Comparative analysis with existing diagnostic markers such as aCL and LA.

Main Results:

• Antibodies against phosphatidylserine-prothrombin complex (aPS/PT) demonstrated diagnostic value for APS.
• The diagnostic performance of aPS/PT was found to be comparable to that of anticardiolipin antibodies (aCL).
• A significant association was observed between aPS/PT and the presence of APS and lupus anticoagulant (LA).

Conclusions:

• aPS/PT antibodies represent a promising biomarker for antiphospholipid syndrome (APS).
• The diagnostic value of aPS/PT is similar to anticardiolipin antibodies (aCL), suggesting its clinical relevance.
• Further investigation of aPS/PT is warranted for its potential inclusion as a laboratory criterion in APS classification.